In contrast to the successful adoption of the GPCR biased signaling idea for therapeutic benefit in the cardiovascular, neurological, and behavior sectors, there have been no publications establishing the efficacy of GPCR biased signaling for the treatment of cancer. Here, LPAR3 is linked to cancer.